转自：证券时报 人民财讯8月4日电，福元医药(601089)8月4日晚间发布股票交易异常波动的公告，公司股票连续三个交 易日收盘价格涨幅偏离值累计达到20%。公司关注到近期市场对创新药业务关注度较高。公司此前披 露，公司1类创新药FY101注射液获得药物临床试验批准通知书，截至公告披露日，该项目尚处于I期临 床试验阶段，试验能否成功还存在重大不确定性。 ...

福元医药8月4日公告，公司股票连续三个交易日收盘价格涨幅偏离值累计达到20%，属于股票交易异常 波动情形。 经核实，公司及子公司的生产经营活动一切正常，内外部环境未发生重大变化，不存在应 披露而未披露的重大事项。公司关注到近期市场对创新药业务关注度较高。公司1类创新药FY101注射 液获得药物临床试验批准通知书，截至本公告披露日，该项目尚处于I期临床试验阶段，试验能否成功 还存在重大不确定性。 ...

Market Overview - As of August 1, the Shanghai Composite Index closed at 3559.95 points, with a decline of 0.37%. The Shenzhen Component Index closed at 10991.32 points, down 0.17%, and the ChiNext Index closed at 2322.63 points, decreasing by 0.24% [1]. Trading Volume Analysis - A total of 1503 stocks saw an increase in average transaction volume, with 31 stocks experiencing a rise of over 50%. Conversely, 3051 stocks reported a decrease in average transaction volume [1]. - Notable stocks with significant increases in average transaction volume include Kecuan Technology, Shenghui Integration, and Zhengzhong Design [1]. Active Stocks by Transaction Volume - The stocks with the highest increase in average transaction volume on August 1 include: - Kecuan Technology: 9.99% increase, average transaction volume of 1014 shares, up 193.10% [3]. - Shenghui Integration: 10.00% increase, average transaction volume of 672 shares, up 191.70% [3]. - Zhengzhong Design: 10.00% increase, average transaction volume of 2134 shares, up 168.74% [3]. Active Stocks by Transaction Count - The stocks with the highest increase in transaction count on August 1 include: - Anzheng Fashion: -1.69% change, with 68,433 transactions, up 1618.56% [2]. - Yingweike: 2.04% change, with 218,079 transactions, up 1082.38% [2]. - Zhongjiabo Chuang: -3.90% change, with 48,487 transactions, up 656.19% [2]. Stocks with Significant Increases in Both Volume and Count - Kecuan Technology stands out with a 9.99% increase, an average transaction volume of 1014 shares (up 193.10%), and a transaction count of 16,921 (up 126.52%) [4]. - Other notable stocks include: - Jiejia Weichuang: 20.00% increase, average transaction volume of 838 shares (up 130.45%), and 57,709 transactions (up 121.19%) [4]. - Riyi Electronics: 10.01% increase, average transaction volume of 846 shares (up 113.00%), and 25,112 transactions (up 161.72%) [4].

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Lansoprazole enteric-coated capsules, indicating approval for production [1] Company Summary - The approved Lansoprazole enteric-coated capsules are available in two specifications: 15mg and 30mg [1] - Lansoprazole was developed by Takeda and was first approved for sale in France on December 31, 1990 [1] - The drug was approved for domestic sale in China on December 6, 1996, and is indicated for conditions such as gastric ulcers, duodenal ulcers, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and anastomotic ulcers [1] Industry Summary - The approval of Lansoprazole enteric-coated capsules reflects ongoing regulatory support for pharmaceutical products aimed at treating gastrointestinal disorders [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-054 北京福元医药股份有限公司 关于兰索拉唑肠溶胶囊获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 公司于 2024 年 4 月 25 日获得申报受理通知书，并于近日获得国 家药监局批准。根据国家相关政策规定，本次获得《药品注册证书》， 为视同通过一致性评价。 截至本公告日，公司针对该药品累计研发投入为人民币 583.23 万元(未经审计)。 三、同类药品的市场状况 米内网数据显示，2024 年中国三大终端六大市场兰索拉唑（口服 剂型：胶囊剂、片剂）的销售额约为 100,571 万元，其中城市公立医 院和县级公立医院销售额为 73,807 万元，城市社区中心和乡镇卫生院 销售额为 16,080 万元，城市实体药店和网上药店销售额为 10,684 万 元。 四、对公司的影响及风险提示 近日，北京福元医药股份有限公司（以下简称"公司"）收到了 国家药品监督管理局（以下简称"国家药监局"）颁发的兰索拉唑肠 溶胶囊（规格：15mg；30mg ...

证券代码：601089 证券简称：福元医药 公告编号：临 2025-053 北京福元医药股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京福元医药股份有限公司(以下简称"公司") 下属全资子公司 福元药业有限公司获得国家药品监督管理局（以下简称"国家药监局"） 核准签发的"水杨酸苯酚贴膏"（以下简称"该药品")《药品补充申 请批准通知书》，该药品上市许可持有人由西安康华药业有限公司变 更为福元药业有限公司。现将相关情况公告如下： 一、通知书基本信息 受理号：CYHB2501310 通知书编号：2025B03449 上市许可持有人：福元药业有限公司 生产企业：福元药业有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品此次申请事项符合药品注册的有关要求，同意按照《药品 上市后变更管理办法（试行）》相关规定，批准本品上市许可持有人 由"西安康华药业有限公司"变更为"福元药业有限公司"，药品批 准文号不变。转让药品的生产场地、处方、生产工艺、质量 ...

Group 1 - The core point of the article is that Fuyuan Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its product, Lianbenbengzhuo Solution, which allows for its production [2]. Group 2 - Fuyuan Pharmaceutical's subsidiary, Fuyuan Pharmaceutical Co., Ltd., is responsible for the production of Lianbenbengzhuo Solution [2]. - The approval of the drug registration certificate signifies a regulatory milestone for the company, potentially enhancing its product portfolio [2].

证券代码：601089 证券简称：福元医药 公告编号：临 2025-052 | | 批准注册，发给药品注册证书。质量标准、说 | | --- | --- | | | 明书、标签及生产工艺照所附执行。药品生产 企业应当符合药品生产质量管理规范要求方可 | | | 生产销售。 | | 上市许可持有人 | 福元药业有限公司 | | 生产企业 | 福元药业有限公司 | 二、药品相关信息 该药品用于下列皮肤真菌病的治疗： （一）白癣：足部白癣、体部白癣、股部白癣。 （二）念珠菌症：指间糜烂症、间擦疹、皮肤念珠菌症。 北京福元医药股份有限公司 关于联苯苄唑溶液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，北京福元医药股份有限公司（以下简称"公司"）全资子 公司福元药业有限公司（以下简称"福元药业"）收到了国家药品监 督管理局（以下简称"国家药监局"）颁发的联苯苄唑溶液（规格： 1%(10 毫升：0.1 克)，以下简称"该药品"）《药品注册证书》(证书 编号：2025S02274)，批准该药品生产。现将相关 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received a drug registration certificate from the National Medical Products Administration for its product, a 1% solution of bifonazole, which is approved for production [1]. Group 1: Product Approval - Fuyuan Pharmaceutical's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has been granted a drug registration certificate for bifonazole solution (specification: 1% (10ml: 0.1g)) [1]. - The drug is indicated for the treatment of various skin fungal diseases, including tinea (foot, body, and groin), candidiasis (interdigital maceration, intertrigo, and cutaneous candidiasis), and vitiligo [1].